2022
MIF is a common genetic determinant of COVID-19 symptomatic infection and severity
Shin JJ, Fan W, Par-Young J, Piecychna M, Leng L, Israni-Winger K, Qing H, Gu J, Zhao H, Schulz WL, Unlu S, Kuster J, Young G, Liu J, Ko AI, Garcia A, Sauler M, Wisnewski AV, Young L, Orduña A, Wang A, Klementina O, Garcia AB, Hegyi P, Armstrong ME, Mitchell P, Ordiz DB, Garami A, Kang I, Bucala R. MIF is a common genetic determinant of COVID-19 symptomatic infection and severity. QJM 2022, 116: 205-212. PMID: 36222594, PMCID: PMC9620729, DOI: 10.1093/qjmed/hcac234.Peer-Reviewed Original ResearchConceptsMacrophage migration inhibitory factorLow-expression MIF alleleCOVID-19 infectionMIF allelesCATT7 alleleHealthy controlsCOVID-19Serum macrophage migration inhibitory factorSymptomatic SARS-CoV-2 infectionHigher serum MIF levelsHigh-expression MIF allelesRetrospective case-control studySARS-CoV-2 infectionFunctional polymorphismsAvailable clinical characteristicsMultinational retrospective studySerum MIF levelsUninfected healthy controlsSymptomatic COVID-19Tertiary medical centerHealthy control subjectsCase-control studyMigration inhibitory factorCoronavirus disease 2019Common functional polymorphismsEffect of androgen receptor directed therapy in prostate cancer patients with COVID-19.
Unlu S, Shin J, Par-Young J, Vinetz J, Petrylak D, Kang I, Kim J. Effect of androgen receptor directed therapy in prostate cancer patients with COVID-19. Journal Of Clinical Oncology 2022, 40: 161-161. DOI: 10.1200/jco.2022.40.6_suppl.161.Peer-Reviewed Original ResearchProstate cancerPCa patientsAndrogen receptorCOVID-19Mortality rateYale New Haven Health SystemProtective rolePrevalence of PCaRate of hospitalRetrospective chart reviewExpression of TMPRSS2Rate of hospitalizationProstate cancer patientsAndrogen receptor antagonistProstate cancer casesSARS-CoV-2Institutional review boardDirected therapyChart reviewClinical characteristicsGnRH agonistHormone therapyGnRH antagonistHome medicationsClinical outcomes
2021
Low IgG trough and lymphocyte subset counts are associated with hospitalization for COVID-19 in patients with primary antibody deficiency
Kuster JK, Unlu S, Makin TA, Par-Young J, Simonov M, Shafi S, Balanda M, Randolph C, Steele R, Hsu FI, Price C, Kohli-Pamnani A, Borish L, Lawrence MG, Kang I, Shin JJ. Low IgG trough and lymphocyte subset counts are associated with hospitalization for COVID-19 in patients with primary antibody deficiency. The Journal Of Allergy And Clinical Immunology In Practice 2021, 10: 633-636.e3. PMID: 34929372, PMCID: PMC8683251, DOI: 10.1016/j.jaip.2021.11.030.Peer-Reviewed Original ResearchA distinct association of inflammatory molecules with outcomes of COVID-19 in younger versus older adults
Shin JJ, Jeon S, Unlu S, Par-Young J, Shin MS, Kuster JK, Afinogenova Y, Kang Y, Simonov M, Buller G, Bucala R, Kang I. A distinct association of inflammatory molecules with outcomes of COVID-19 in younger versus older adults. Clinical Immunology 2021, 232: 108857. PMID: 34560283, PMCID: PMC8455237, DOI: 10.1016/j.clim.2021.108857.Peer-Reviewed Original ResearchConceptsClinical outcomesOlder adultsInflammatory moleculesHospitalized adult COVID-19 patientsOlder subjectsAdult COVID-19 patientsSoluble IL-2 receptor alphaIL-2 receptor alphaCOVID-19Different immunologic mechanismsAcute phase reactantsCOVID-19 patientsDevastating clinical outcomesT cell activationImmunologic mechanismsIL-10Immune agingInflammatory processImmune mechanismsPhase reactantsSevere diseaseReceptor alphaCell activationDisease severityBiological predictors
2020
Diagnosis of SARS-CoV-2 infection in the setting of the cytokine release syndrome
Azar MM, Shin JJ, Kang I, Landry M. Diagnosis of SARS-CoV-2 infection in the setting of the cytokine release syndrome. Expert Review Of Molecular Diagnostics 2020, 20: 1087-1097. PMID: 32990479, DOI: 10.1080/14737159.2020.1830760.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Immune profileCOVID-19SARS-CoV-2 infectionCytokine release syndromeAdaptive immune cellsMultiple inflammatory cytokinesSARS-CoV-2 RNAFalse-negative resultsRelease syndromeInfectious complicationsIL-10Laboratory markersD-dimerInflammatory moleculesIP-10IL-6Inflammatory cytokinesMCP-1Acute diagnosisIL-2Immune cellsClinical severityTherapeutic benefitPathogenic contribution